Karuna Therapeutics Inc
NASDAQ:KRTX 10:23:14 AM EDT
Products
Karuna Therapeutics Announces Global License Agreement
Published: 02/02/2023 13:10 GMT
Karuna Therapeutics Inc (KRTX) - Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio’s Investigational Trpc4/5 Product Candidates.
Karuna Therapeutics Inc - Goldfinch Bio Assignment Estate to Receive $15 Million Upfront Payment.
Karuna Therapeutics Inc - to Share Details on Planned Development of Gfb-887 for Treatment of Mood and Anxiety Disorders in Second Half of 2023.
Karuna Therapeutics Inc - Goldfinch Bio Assignment Estate to Receive Up to $520 Million in Potential Milestone Payments Plus Royalties.
Karuna Therapeutics Inc-co to Obtain Exclusive Global License to Develop, Manufacture, Commercialize Multiple Trpc4/5 Candidates.
Karuna Therapeutics Inc - Goldfinch Bio Assignment Estate to Receive $15 Million Upfront Payment.
Karuna Therapeutics Inc - to Share Details on Planned Development of Gfb-887 for Treatment of Mood and Anxiety Disorders in Second Half of 2023.
Karuna Therapeutics Inc - Goldfinch Bio Assignment Estate to Receive Up to $520 Million in Potential Milestone Payments Plus Royalties.
Karuna Therapeutics Inc-co to Obtain Exclusive Global License to Develop, Manufacture, Commercialize Multiple Trpc4/5 Candidates.